Page 1

BRUKER Bruker Reports First Quarter 2021 Financial Results • Q1 2021 revenue growth of 30.8 % year - over - year , organic revenue growth of 23.8 % • Q1 2021 GAAP EPS of $ 0.37 ; non - GAAP EPS of $ 0.44 , compared to $ 0.14 in Q1 2020 • Raising fiscal year 2021 outlook on strong demand for the Company's high - performance life science tools , scientific instruments and diagnostic solutions BILLERICA , Massachusetts - May 5 , 2021 - Bruker Corporation ( Nasdaq : BRKR ) today announced financial results for its first quarter ended March 31 , 2021 . First Quarter 2021 Financial Results Bruker's revenues for the first quarter of 2021 were $ 554.7 million , an increase of 30.8 % compared to $ 424.0 million in the first quarter of 2020. In the first quarter of 2021 , on an organic basis , Bruker's revenues grew 23.8 % year - over - year . Foreign currency translation had a positive effect of 6.2 % and growth from acquisitions added 0.8 % . First quarter 2021 Bruker Scientific Instruments ( BSI ) revenues of $ 506.2 million increased 32.7 % compared to the first quarter of 2020 , including organic revenue growth of 25.6 % . The revenue growth reflected strong demand for Bruker's high performance life science tools , scientific instruments and diagnostic solutions , with greater than 20 % year - over - year organic revenue increases in all three Bruker Scientific Instruments ( BSI ) groups . First quarter 2021 Bruker Energy & Supercon Technologies ( BEST ) revenues of $ 52.4 million increased 13.4 % compared to the first quarter of 2020 , including an organic revenue increase , net of intercompany eliminations , of 7.1 % . First quarter 2021 GAAP operating income was $ 89.1 million , compared to $ 16.4 million in the first quarter of 2020 , representing GAAP operating margins of 16.1 % and 3.9 % , respectively . Non - GAAP operating income in the first quarter of 2021 was $ 102.2 million , compared to $ 32.2 million in the first quarter of 2020. Bruker's first quarter 2021 non - GAAP operating margin was 18.4 % , compared to 7.6 % in the first quarter of 2020 . First quarter 2021 GAAP diluted earnings per share ( EPS ) were $ 0.37 , compared to $ 0.07 in the first quarter of 2020. First quarter 2021 non - GAAP diluted EPS were $ 0.44 , compared to $ 0.14 in the first quarter of 2020. The year - over - year increases in the Company's GAAP and non - GAAP operating income , operating margins and EPS were due to the higher revenues , improved gross margins and favorable operating expense leverage . A reconciliation of non - GAAP to GAAP financial measures is provided in the tables accompanying this press release . Frank H. Laukien , President and CEO of Bruker , commented : " Bruker had an excellent start to 2021 , with strong year - over - year revenue growth and remarkable operating performance improvements . During the quarter , we experienced strong revenue growth for our Project Accelerate products and solutions , particularly for proteomics and biopharma solutions , as well as for our core scientific instruments from strengthening academic , applied , industrial and semiconductor markets . " Dr. Laukien continued : " With robust Scientific Instruments order trends in the first quarter , we are raising our full year 2021 revenue growth , operating margin and earnings outlook . We believe Bruker is now well positioned for